FEMERIS Women’s Health Research Center is a multi-discipline research center within Medical Diagnostic Laboratories, L.L.C.(MDL) dedicated to discovery and development of diagnostic biomarkers, therapeutic targets, and engineered probiotics in the detection and treatment of obstetric and gynecologic infectious diseases and medical conditions.
Our goal is to understand medical issues that affect women’s health and translate our research findings to advance clinical analytics, drug discovery, and ultimately leading to medical therapy.
We also serve as a resource for research and pre-clinical studies through collaborations with clinicians and research scientists.
FEMERIS is a member of the Genesis Biotechnology Group ™ (GBG) located in Hamilton, New Jersey, and is easily accessible to other academic research and medical centers, biotech companies, and pharmaceutical companies in the New York/New Jersey/Pennsylvania area.
10/2015 - FEMERIS publication: Schuyler JA, Mordechai E, Adelson ME, Sobel JD, Gygax SE, Hilbert DW. Identification of intrinsically metronidazole-resistant clades of Gardnerella vaginalis. in Diagn Microbiol Infect Dis..
9/2015 - FEMERIS publication: Schuyler JA, Chadwick SG, Mordechai E, Adelson ME, Gygax SE, Hilbert DW. Draft Genome Sequence of a Metronidazole-Resistant Gardnerella vaginalis Isolate. in Genome Announc..
9/2015 - FEMERIS publication: Schuyler JA, Mordechai E, Adelson ME, Gygax SE, Hilbert DW. Draft Genome Sequence of a Metronidazole-Susceptible Atopobium vaginae Isolate. in Genome Announc..
7/2014 - Genesis Biotechnology Group (GBG) sponsored a two-day symposium on June 18th and 19th entitled “The Vaginal Microbiome and Bacterial Vaginosis.” Read Full Story
7/2014 - FEMERIS publication: Smith WL, Hedges S, Mordechai E, Adelson ME, Trama J, Gygax SE, Kaunitz AK, Hilbert DW. Cervical and vaginal flora is highly concordant with respect to bacterial vaginosis-associated organisms and commensal lactobacillus species in reproductive-aged women. J. Clin. Micrbiol. In Press.
7/2014 - FEMERIS publication: Whaley S, Caudle K, Vermitsky J-P, Chadwick SG, Toner G, Barker K, Gygax SE, Rogers PD. UPC2A is required for high-level azole antifungal resistance in Candida glabrata. Antimicrob. Agents Chemother. In Press.
10/2013 - FEMERIS Research Associate, Geoffrey Toner, and Director Dr. Scott Gygax had a manuscript entitled, “Novel antifungal drug discovery based on targeting pathways regulating the fungal-conserved Upc2 transcription factor” accepted into the journal Antimicrobial Agents and Chemotherapy.
9/2013 - FEMERIS Director Dr. Scott Gygax presented work done by Research Associate Sean Chadwick in a poster entitled “Disruption of Gardnerella vaginalis biofilms with clindamycin and metronidazole” at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy in Denver, Colorado.
8/2013 - FEMERIS Research Associate, Geoffrey Toner, and Director Dr. Scott Gygax had a manuscript entitled, “Flucytosine antagonism of azole activity versus Candida glabrata: role of transcription factor Pdr1 and multidrug transporter Cdr1” accepted into the journal Antimicrobial Agents and Chemotherapy.
5/2013 - FEMERIS Research Associates, Lamar Smith and Sean Chadwick, and Director Dr. Scott Gygax had a manuscript entitled, “Detection of epidemic USA300 community-associated MRSA strains using a single allele-specific PCR targeting a novel polymorphism of Staphylococcus aureus pbp3” accepted into the Journal of Clinical Microbiology.
1/2013 - FEMERIS Director Dr. Scott Gygax had a manuscript entitled, “Mixed vaginitis- more than coinfection and with therapeutic implications” accepted into the journal Current Infectious Disease Reports.
1/2013 - FEMERIS Research Associates, Jessica Schuyler and Sean Chadwick, and Director Dr. Scott Gygax had a manuscript entitled, “X-Plate Technology™: A new method for detecting fluconazole resistance in Candida species” accepted into the Journal of Medical Microbiology.